S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Federal student loan payments are starting again. Here's what you need to know
Bank of Japan survey shows manufacturers optimistic about economy
BREAKING: Tiny biotech successfully treats blindness (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
The UAE holds a major oil and gas conference just ahead of hosting UN COP28 climate talks in Dubai
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Federal student loan payments are starting again. Here's what you need to know
Bank of Japan survey shows manufacturers optimistic about economy
BREAKING: Tiny biotech successfully treats blindness (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
The UAE holds a major oil and gas conference just ahead of hosting UN COP28 climate talks in Dubai
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Federal student loan payments are starting again. Here's what you need to know
Bank of Japan survey shows manufacturers optimistic about economy
BREAKING: Tiny biotech successfully treats blindness (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
The UAE holds a major oil and gas conference just ahead of hosting UN COP28 climate talks in Dubai
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Federal student loan payments are starting again. Here's what you need to know
Bank of Japan survey shows manufacturers optimistic about economy
BREAKING: Tiny biotech successfully treats blindness (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
The UAE holds a major oil and gas conference just ahead of hosting UN COP28 climate talks in Dubai

Bristol-Myers Squibb (BMY) Stock Forecast, Price & News

$58.04
-0.10 (-0.17%)
(As of 09/29/2023 08:52 PM ET)
Compare
Today's Range
$57.87
$58.46
50-Day Range
$57.89
$64.74
52-Week Range
$57.61
$81.43
Volume
10.90 million shs
Average Volume
9.02 million shs
Market Capitalization
$121.25 billion
P/E Ratio
15.44
Dividend Yield
3.93%
Price Target
$69.64

Bristol-Myers Squibb MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
20.0% Upside
$69.64 Price Target
Short Interest
Healthy
1.77% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.30
Upright™ Environmental Score
News Sentiment
0.88mentions of Bristol-Myers Squibb in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$1.15 M Sold Last Quarter
Proj. Earnings Growth
5.65%
From $7.43 to $7.85 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.29 out of 5 stars

Medical Sector

9th out of 970 stocks

Pharmaceutical Preparations Industry

3rd out of 443 stocks


BMY stock logo

About Bristol-Myers Squibb (NYSE:BMY) Stock

The Bristol-Myers Squibb Company is a leading global biopharmaceutical company with a long and impressive history of innovating and developing medicines that improve the lives of patients around the world. Founded in 1887 when William McLaren Bristol and John Ripley Myers purchased the Clinton Pharmaceutical Company, the company was initially named Bristol, Myers and Company. Its first nationally recognized product, Sal Hepatica, was released in the 1890s.

Bristol Myers-Squibb offers chemically synthesized drugs and biologics administered through injections or infusions to patients. The company's pharmaceutical portfolio includes a large number of well-known products. BMS's primary research and development sites are in New Jersey, California, Spain, Massachusetts, New York, Belgium, Japan, India and Massachusetts. The company's products sell to wholesalers and distributors around the world.

Bristol Myers-Squibb has a robust pipeline of investigational medicines in its pipeline. In addition, the company has established strategic collaborations and partnerships with various companies, successfully launching new products. These partnerships and investments generate portions of the company's revenue. 

Bristol Myers-Squibb has acquired several companies over the years, including Medarex in 2009, ZymoGenetics in 2010, Inhibitex Inc. in 2012, Amylin Pharmaceuticals in 2012, iPierian in 2014, Flexus Biosciences in 2015, Cardioxyl in 2015, Padlock Therapeutics in 2016, Cormorant Pharmaceuticals in 2017, IFM Therapeutics in 2017, Celgene in 2019, Otezla in 2019, Forbius in 2020, MyoKardia in 2020 and Turning Point Therapeutics in 2022.

In 2005, the company divested individual consumer products and its subsequent consumer products businesses. In December 2014, the company received FDA approval for its cancer drug, Opdivo, used to treat skin cancers that do not respond to drug therapies. In 2019, the company divested its consumer health business, UPSA, to Taisho. 

The company has also faced several scandals, lawsuits and investigations over the years, the biggest of which is the ongoing $1 billion lawsuit from Guatemala for the company's role in a 1940s experiment that infected hundreds with syphilis. In 2001 BMS faced an accounting scandal that resulted in a restatement of revenues from 1999 to 2001. In 2002, BMS faced a lawsuit based on illegally maintaining a monopoly on Taxol, a chemotherapy medication. The former head of the pharma group and the ex-CFO were indicted for federal securities violations in 2005. In July of 2006, an FBI raid on the company's corporate offices revealed that the company took steps to delay the release of a generic version of one of its drugs.  

BMS began a significant restructuring in 2009, focusing on the pharmaceutical business and biologic products, productivity initiatives and cost-cutting. The U.S. attorney forced the company into oversight and appointed a monitor as part of a deferred prosecution agreement. Lou Schmukler joined Bristol-Myers Squibb in 2010 as global product development and design president. 

In 2013, Forbes magazine ranked the company as the drug company of the year. Dr. Giovanni Caforio took the reigns as CEO in 2015. In 2017, reports began to surface that activist investor Carl Icahn took a stake in the company, widely seen as a signal for a potential future takeover. 

As Bristol-Myers Squibb continues to experience success and growth, the company is committed to delivering innovative treatments to patients and staying ahead of the curve in the biopharmaceutical industry. With its focus on research and development and a long and rich history of delivering innovative medicines, BMS offers an excellent long-term investment opportunity.

BMY Price History

BMY Stock News Headlines

Argenx's 28% Surge & Promising Product Propel Investor Confidence (BMY)
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Bristol-Myers: Out Of Favor (Rating Upgrade)
Bristol-Myers Squibb: How Cheap Is Cheap Enough?
3 Dividend Stocks to Buy and Hold Until Retirement
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Analysts Set Bristol-Myers Squibb (NYSE:BMY) Target Price at $70.67
Morgan Stanley Keeps Their Sell Rating on Bristol-Myers Squibb (BMY)
See More Headlines
Receive BMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bristol-Myers Squibb and its competitors with MarketBeat's FREE daily newsletter.

BMY Company Calendar

Ex-Dividend for 8/1 Dividend
7/06/2023
Last Earnings
7/27/2023
Dividend Payable
8/01/2023
Today
10/02/2023
Ex-Dividend for 11/1 Dividend
10/05/2023
Next Earnings (Confirmed)
10/26/2023
Dividend Payable
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
11012210
Employees
34,300
Year Founded
1887

Price Target and Rating

Average Stock Price Forecast
$69.64
High Stock Price Forecast
$85.00
Low Stock Price Forecast
$56.00
Forecasted Upside/Downside
+20.0%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
16 Analysts

Profitability

Net Income
$6.33 billion
Pretax Margin
19.25%

Debt

Sales & Book Value

Annual Sales
$45.19 billion
Cash Flow
$12.62 per share
Book Value
$14.64 per share

Miscellaneous

Outstanding Shares
2,089,103,000
Free Float
2,087,223,000
Market Cap
$121.25 billion
Optionable
Optionable
Beta
0.42

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Giovanni Caforio M.D. (Age 58)
    Chairman & CEO
    Comp: $5.76M
  • Mr. David V. ElkinsMr. David V. Elkins (Age 55)
    Exec. VP & CFO
    Comp: $2.72M
  • Dr. Christopher S. Boerner Ph.D.Dr. Christopher S. Boerner Ph.D. (Age 52)
    Exec. VP, COO & Director
    Comp: $2.62M
  • Ms. Sandra Leung Esq.Ms. Sandra Leung Esq. (Age 62)
    Exec. VP & Gen. Counsel
    Comp: $2.66M
  • Mr. Greg Meyers (Age 50)
    Exec. VP and Chief Digital & Technology Officer
  • Mr. Timothy Power
    VP & Head of Investor Relations
  • Ms. Cari Gallman
    Sr. VP & Chief Compliance and Ethics Officer
  • Ms. Ann M. Powell Judge (Age 57)
    Exec. VP & Chief HR Officer
  • Dr. Fouad Namouni M.D. (Age 54)
    Head of Oncology Devel.
  • Mr. Samit Hirawat M.D. (Age 54)
    Exec. VP & Chief Medical Officer of Drug Devel.













BMY Stock - Frequently Asked Questions

Should I buy or sell Bristol-Myers Squibb stock right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last year. There are currently 2 sell ratings, 8 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BMY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BMY, but not buy additional shares or sell existing shares.
View BMY analyst ratings
or view top-rated stocks.

What is Bristol-Myers Squibb's stock price forecast for 2023?

16 equities research analysts have issued 1 year price objectives for Bristol-Myers Squibb's stock. Their BMY share price forecasts range from $56.00 to $85.00. On average, they anticipate the company's stock price to reach $69.64 in the next twelve months. This suggests a possible upside of 20.0% from the stock's current price.
View analysts price targets for BMY
or view top-rated stocks among Wall Street analysts.

How have BMY shares performed in 2023?

Bristol-Myers Squibb's stock was trading at $71.95 at the beginning of 2023. Since then, BMY stock has decreased by 19.3% and is now trading at $58.04.
View the best growth stocks for 2023 here
.

Are investors shorting Bristol-Myers Squibb?

Bristol-Myers Squibb saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 36,980,000 shares, a decline of 15.5% from the August 31st total of 43,760,000 shares. Based on an average daily trading volume, of 10,540,000 shares, the short-interest ratio is presently 3.5 days. Approximately 1.8% of the shares of the stock are sold short.
View Bristol-Myers Squibb's Short Interest
.

When is Bristol-Myers Squibb's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our BMY earnings forecast
.

How can I listen to Bristol-Myers Squibb's earnings call?

Bristol-Myers Squibb will be holding an earnings conference call on Thursday, October 26th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Bristol-Myers Squibb's earnings last quarter?

Bristol-Myers Squibb (NYSE:BMY) issued its quarterly earnings data on Thursday, July, 27th. The biopharmaceutical company reported $1.75 earnings per share for the quarter, missing analysts' consensus estimates of $1.99 by $0.24. The biopharmaceutical company had revenue of $11.23 billion for the quarter, compared to analysts' expectations of $11.81 billion. Bristol-Myers Squibb had a trailing twelve-month return on equity of 50.51% and a net margin of 17.62%. The business's quarterly revenue was down 5.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.93 EPS.
Read the conference call transcript
.

How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?

Bristol-Myers Squibb announced a quarterly dividend on Wednesday, September 20th. Shareholders of record on Friday, October 6th will be paid a dividend of $0.57 per share on Wednesday, November 1st. This represents a $2.28 annualized dividend and a yield of 3.93%. The ex-dividend date is Thursday, October 5th.
Read our dividend analysis for BMY
.

Is Bristol-Myers Squibb a good dividend stock?

Bristol-Myers Squibb (NYSE:BMY) pays an annual dividend of $2.28 per share and currently has a dividend yield of 3.92%. The company has been increasing its dividend for 16 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 60.64%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, BMY will have a dividend payout ratio of 29.04% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for BMY.

When did Bristol-Myers Squibb's stock split?

Shares of Bristol-Myers Squibb split on the morning of Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly minted shares were distributed to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What guidance has Bristol-Myers Squibb issued on next quarter's earnings?

Bristol-Myers Squibb updated its FY 2023 earnings guidance on Thursday, July, 27th. The company provided EPS guidance of $7.35-$7.65 for the period, compared to the consensus earnings per share estimate of $7.99. The company issued revenue guidance of -.

What is Giovanni Caforio's approval rating as Bristol-Myers Squibb's CEO?

659 employees have rated Bristol-Myers Squibb Chief Executive Officer Giovanni Caforio on Glassdoor.com. Giovanni Caforio has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Bristol-Myers Squibb own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bristol-Myers Squibb investors own include AbbVie (ABBV), AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Intel (INTC), NVIDIA (NVDA), CVS Health (CVS), Cisco Systems (CSCO) and Bank of America (BAC).

What is Bristol-Myers Squibb's stock symbol?

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

How do I buy shares of Bristol-Myers Squibb?

Shares of BMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bristol-Myers Squibb's stock price today?

One share of BMY stock can currently be purchased for approximately $58.04.

How much money does Bristol-Myers Squibb make?

Bristol-Myers Squibb (NYSE:BMY) has a market capitalization of $121.25 billion and generates $45.19 billion in revenue each year. The biopharmaceutical company earns $6.33 billion in net income (profit) each year or $3.76 on an earnings per share basis.

How many employees does Bristol-Myers Squibb have?

The company employs 34,300 workers across the globe.

Does Bristol-Myers Squibb have any subsidiaries?
The following companies are subsidiares of Bristol-Myers Squibb: 1096271 B.C. ULC, 345 Park LLC, A.G. Medical Services P.A., AHI Investment LLC, AbVitro LLC, Abraxis BioScience Australia Pty Ltd., Abraxis BioScience Inc., Abraxis BioScience International Holding Company Inc., Abraxis BioScience LLC, Abraxis BioScience Puerto Rico LLC, Acetylon Pharmaceuticals Inc., Adnexus, Adnexus a Bristol-Myers Squibb R&D Company, Allard Labs Acquisition G.P., Amira Pharmaceuticals, Amira Pharmaceuticals Inc., Amylin Pharmaceuticals, Apothecon LLC, B-MS Generx Unlimited Company, BMS Benelux Holdings B.V., BMS Bermuda Nominees L.L.C., BMS Data Acquisition Company LLC, BMS Forex Company, BMS Holdings Sarl, BMS Holdings Spain S.L., BMS International Insurance Designated Activity Company, BMS Investco SAS, BMS Korea Holdings L.L.C., BMS Latin American Nominees L.L.C., BMS Luxembourg Partners L.L.C., BMS Omega Bermuda Holdings Finance Ltd., BMS Pharmaceutical Korea Limited, BMS Pharmaceuticals Germany Holdings B.V., BMS Pharmaceuticals International Holdings Netherlands B.V., BMS Pharmaceuticals Korea Holdings B.V., BMS Pharmaceuticals Mexico Holdings B.V., BMS Pharmaceuticals Netherlands Holdings B.V., BMS Real Estate LLC, BMS Spain Investments LLC, BMS Strategic Portfolio Investments Holdings Inc., Blisa Acquisition G.P., Bristol (Iran) S.A., Bristol Iran Private Company Limited, Bristol Laboratories Inc., Bristol Laboratories International S.A., Bristol Laboratories Medical Information Systems Inc., Bristol-Myers (Andes) L.L.C., Bristol-Myers (Private) Limited, Bristol-Myers Middle East S.A.L., Bristol-Myers Overseas Corporation, Bristol-Myers Squibb (China) Investment Co. Ltd., Bristol-Myers Squibb (China) Pharmaceuticals Co. Ltd., Bristol-Myers Squibb (Israel) Ltd., Bristol-Myers Squibb (NZ) Limited, Bristol-Myers Squibb (Proprietary) Limited, Bristol-Myers Squibb (Shanghai) Trading Co. Ltd., Bristol-Myers Squibb (Singapore) Pte. Limited, Bristol-Myers Squibb (Taiwan) Ltd., Bristol-Myers Squibb (West Indies) Ltd., Bristol-Myers Squibb A.E., Bristol-Myers Squibb Aktiebolag, Bristol-Myers Squibb Argentina S. R. L., Bristol-Myers Squibb Australia Pty. Ltd., Bristol-Myers Squibb Axia Limited, Bristol-Myers Squibb B.V., Bristol-Myers Squibb Belgium S.A., Bristol-Myers Squibb Business Services Limited, Bristol-Myers Squibb Canada Co., Bristol-Myers Squibb Canada International Limited, Bristol-Myers Squibb Delta Company Limited, Bristol-Myers Squibb Denmark Filial of Bristol-Myers Squibb AB, Bristol-Myers Squibb EMEA Sarl, Bristol-Myers Squibb Egypt LLC, Bristol-Myers Squibb Epsilon Holdings Unlimited Company, Bristol-Myers Squibb Farmaceutica Ltda., Bristol-Myers Squibb Farmaceutica Portuguesa S.A., Bristol-Myers Squibb GesmbH, Bristol-Myers Squibb GmbH & Co. KGaA, Bristol-Myers Squibb Holding Germany GmbH & Co. KG, Bristol-Myers Squibb Holdings 2002 Limited, Bristol-Myers Squibb Holdings Germany Verwaltungs GmbH, Bristol-Myers Squibb Holdings Ireland Unlimited Company, Bristol-Myers Squibb Holdings Limited, Bristol-Myers Squibb Holdings Pharma Ltd. Liability Company, Bristol-Myers Squibb Ilaclari Inc., Bristol-Myers Squibb India Pvt. Limited, Bristol-Myers Squibb International Company Unlimited Company, Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb Investco L.L.C., Bristol-Myers Squibb K.K., Bristol-Myers Squibb Kft., Bristol-Myers Squibb Luxembourg International S.C.A., Bristol-Myers Squibb Luxembourg S.a.r.l., Bristol-Myers Squibb MEA GmbH, Bristol-Myers Squibb Manufacturing Company, Bristol-Myers Squibb Marketing Services S.R.L., Bristol-Myers Squibb Middle East & Africa FZ-LLC, Bristol-Myers Squibb Norway Ltd., Bristol-Myers Squibb Nutricionales de Mexico S. de R.L. de C.V., Bristol-Myers Squibb Peru S.A., Bristol-Myers Squibb Pharma (HK) Ltd, Bristol-Myers Squibb Pharma (Thailand) Limited, Bristol-Myers Squibb Pharma Company, Bristol-Myers Squibb Pharma EEIG, Bristol-Myers Squibb Pharma Holding Company LLC, Bristol-Myers Squibb Pharma Ventures Corporation, Bristol-Myers Squibb Pharmaceuticals Limited, Bristol-Myers Squibb Pharmaceuticals Unlimited Company, Bristol-Myers Squibb Polska Sp. z o.o., Bristol-Myers Squibb Products SA, Bristol-Myers Squibb Puerto Rico Inc., Bristol-Myers Squibb Puerto Rico/Sanofi Pharmaceutical Partnership Puerto Rico, Bristol-Myers Squibb Romania S.R.L., Bristol-Myers Squibb S.A.U., Bristol-Myers Squibb S.r.l., Bristol-Myers Squibb SA, Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Bristol-Myers Squibb Sarl, Bristol-Myers Squibb Service Ltd., Bristol-Myers Squibb Services Sp. z o.o., Bristol-Myers Squibb Spol. s r.o., Bristol-Myers Squibb Theta Finance Ltd., Bristol-Myers Squibb Trustees Limited, Bristol-Myers Squibb Verwaltungs GmbH, Bristol-Myers Squibb de Colombia S.A., Bristol-Myers Squibb de Costa Rica Sociedad Anonima, Bristol-Myers Squibb de Guatemala S.A., Bristol-Myers Squibb de Mexico S. de R.L. de C.V., Bristol-Myers Squibb/Astrazeneca EEIG, Bristol-Myers Squibb/Pfizer EEIG, Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, Bristol-Myers de Venezuela S.C.A., CHT I LLC, CHT II LLC, CHT III LLC, CHT IV LLC, CR Finance Company LLC, Cardioxyl Pharmaceuticals, Cardioxyl Pharmaceuticals Inc., Celem LLC, Celem Ltd., Celgene, Celgene A.B., Celgene AS, Celgene Ab (Finland), Celgene Alpine Investment Co. II LLC, Celgene Alpine Investment Co. III LLC, Celgene Alpine Investment Co. LLC, Celgene ApS, Celgene B.V., Celgene BVBA, Celgene Brasil Produtos Farmacêuticos Ltda., Celgene CAR LLC, Celgene CAR Ltd., Celgene Chemicals Sarl, Celgene China Holdings LLC, Celgene Co., Celgene Corporation, Celgene Distribution B.V., Celgene EngMab GmbH, Celgene Europe B.V., Celgene Europe Limited, Celgene European Investment Company LLC, Celgene Financing Company LLC, Celgene Global Holdings Sarl, Celgene GmbH [Austria], Celgene GmbH [Germany], Celgene GmbH [Switzerland], Celgene Holdings East Corporation, Celgene Holdings II Sarl, Celgene Holdings III Sarl, Celgene Ilaç Pazarlama ve Ticaret Limited Şirketi, Celgene Inc., Celgene International Holdings Corporation, Celgene International II Sàrl, Celgene International III Sàrl, Celgene International Inc., Celgene International Sàrl, Celgene K.K., Celgene Kft., Celgene Limited [Hong Kong], Celgene Limited [Ireland], Celgene Limited [New Zealand], Celgene Limited [Taiwan], Celgene Limited [UK], Celgene Logistics Sàrl, Celgene Ltd, Celgene Luxembourg Sarl, Celgene Management Sàrl, Celgene NJ Investment Co, Celgene Netherlands B.V., Celgene Netherlands Investment B.V., Celgene Pharmaceutical (Shanghai) Co. Ltd., Celgene Pte. Ltd., Celgene Pty Ltd, Celgene Puerto Rico Distribution LLC, Celgene Quanticel Research Inc, Celgene R&D Sàrl, Celgene RIVOT LLC, Celgene RIVOT Ltd., Celgene RIVOT SRL, Celgene Receptos Limited, Celgene Receptos Sàrl, Celgene Research Incubator At Summit West LLC, Celgene Research S.L.U., Celgene Research and Development Company LLC, Celgene Research and Development I ULC, Celgene Research and Development II LLC, Celgene Research and Investment Company II LLC, Celgene S. de R.L. de C.V., Celgene S.L.U., Celgene S.R.L., Celgene SAS, Celgene Sarl AU, Celgene Sdn Bhd, Celgene Services Sàrl, Celgene Sociedade Unipessoal Lda, Celgene Sp. Z.o.o., Celgene Sro [Czech Republic], Celgene Summit Investment Co, Celgene Switzerland Holding Sarl, Celgene Switzerland II LLC, Celgene Switzerland Investment Sarl, Celgene Switzerland LLC, Celgene Switzerland Sarl, Celgene Tri A Holdings Ltd., Celgene Tri Sarl, Celgene UK Distribution Limited, Celgene UK Holdings Limited, Celgene UK Manufacturing II Limited, Celgene UK Manufacturing III Limited, Celgene UK Manufacturing Limited, Celgene d.o.o., Celgene sro [Slovakia], Celmed LLC, Celmed Ltd., ConvaTec Divestiture, Cormorant Pharmaceuticals, Cormorant Pharmaceuticals AB, Crosp Ltd., Delinia Inc., Deuteria Pharmaceuticals Inc., DuPont Pharmaceuticals, E. R. Squibb & Sons Inter-American Corporation, E. R. Squibb & Sons L.L.C., E. R. Squibb & Sons Limited, EWI Corporation, EngMab Sarl, F-star Alpha, FermaVir Pharmaceuticals L.L.C., FermaVir Research L.L.C., Flexus Biosciences, Flexus Biosciences Inc., Forbius, Galecto Biotech, GenPharm International L.L.C., Gloucester Pharmaceuticals LLC, Grove Insurance Company Ltd., Heyden Farmaceutica Portuguesa Limitada, IFM Therapeutics, Impact Biomedicines Inc., Inhibitex, Inhibitex L.L.C., Innate Tumor Immunity Inc., JuMP Holdings LLC, Juno Therapeutics GmbH, Juno Therapeutics Inc., Kosan Biosciences, Kosan Biosciences Incorporated, Linson Investments Limited, Mead Johnson (Manufacturing) Jamaica Limited, Mead Johnson Jamaica Ltd., Medarex, Morris Avenue Investment II LLC, Morris Avenue Investment LLC, MyoKardia, O.o.o. Bristol-Myers Squibb, Oy Bristol-Myers Squibb (Finland) AB, Padlock Therapeutics, Padlock Therapeutics Inc., Pharmion LLC, Princeton Pharmaceutical Products Inc., Receptos LLC, Receptos Services LLC, RedoxTherapies Inc., Route 22 Real Estate Holding Corporation, SPV A Holdings ULC, Seamair Insurance DAC, Signal Pharmaceuticals LLC, Sino-American Shanghai Squibb Pharmaceuticals Limited, Societe Francaise de Complements Alimentaires(S.O.F.C.A.), Squibb Middle East S.A., Summit West Celgene LLC, Swords Laboratories, VentiRx Pharmaceuticals Inc., Westwood-Intrafin SA, Westwood-Squibb Pharmaceuticals Inc., X-Body Inc., ZymoGenetics, ZymoGenetics Inc., ZymoGenetics LLC, ZymoGenetics Paymaster LLC, iPierian, and iPierian Inc..
Read More
How can I contact Bristol-Myers Squibb?

Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The official website for the company is www.bms.com. The biopharmaceutical company can be reached via phone at (212) 546-4000, via email at john.elicker@bms.com, or via fax at 212-546-4020.

This page (NYSE:BMY) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -